Strategic partnerships Olatec is a Phase 2 biotech focused on NLRP3 inhibitors with international trials and a strong safety/efficacy profile. Target potential collaborations with pharma companies pursuing inflammatory diseases, neuroinflammation, diabetes complications, and oncology to co-develop or license rights for later-stage programs and expansion into new geographies.

Clinical advisory leverage The company continually expands its clinical and advisory footprint with high-profile clinicians and institutions. Use this to position joint development or sponsored research opportunities, clinical trial with CROs, and advisory boards for co-authored publications, accelerating engagement with academic and patient-centered organizations.

Inflammation focus Dapansutrile targets inflammatory pathways with potential across multiple indications. Sales targets include contract research services, biomarker-driven study collaborations, and companion diagnostics development with pharma partners seeking immune modulation therapies in arthritis, Parkinson’s disease, diabetes, and cancer settings.

Global trial expansion With operations in the United States and Europe and ongoing Phase 2 trials in the U.K., there are opportunities to offer regional CRO partnerships, regulatory affairs support, and manufacturing/co-development services to streamline international trial conduct and accelerate time-to-market for potential therapies.

Financial runway Current funding and a sizable Series A history indicate liquidity for strategic collaborations, licensing deals, and milestone-based partnerships. Target M&A-ready or co-development discussions that align with growth capital needs while offering potential upside through revenue sharing or milestone payments.